Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 181.65 -0.19% -0.34
ALXN closed down 0.19 percent on Friday, June 11, 2021, on 69 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ALXN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 50.15%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 52.81%
Multiple of Ten Bearish Other 52.81%
Inside Day Range Contraction 52.81%
Oversold Stochastic Weakness 52.81%
Stochastic Buy Signal Bullish 54.28%
Multiple of Ten Bearish Other 54.28%
Outside Day Range Expansion 54.28%
Lower Bollinger Band Touch Weakness 54.28%
Oversold Stochastic Weakness 54.28%
Older End-of-Day Signals for ALXN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alexion Pharmaceuticals, Inc. Description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.


Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Medicine Biopharmaceutical Nasdaq 100 Organ Systems Clinics Healthcare Providers Therapeutic Product Therapeutic Products Genetic Disease Hemoglobin Metabolic Disorders C3 Hemoglobinuria Inflammatory Disorders Myasthenia Myasthenia Gravis Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Hemolytic Uremic Syndrome Humanized Antibody Kidney Transplant Pnh Atypical Hemolytic Uremic Syndrome Blood Disorder Blood Disorders Hospital Buying Groups Renal Transplant

Is ALXN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 182.605
52 Week Low 99.91
Average Volume 1,850,969
200-Day Moving Average 144.49
50-Day Moving Average 169.08
20-Day Moving Average 176.97
10-Day Moving Average 177.65
Average True Range 1.94
ADX 38.46
+DI 39.42
-DI 14.06
Chandelier Exit (Long, 3 ATRs) 176.79
Chandelier Exit (Short, 3 ATRs) 177.62
Upper Bollinger Bands 181.11
Lower Bollinger Band 172.83
Percent B (%b) 1.06
BandWidth 4.68
MACD Line 2.88
MACD Signal Line 2.87
MACD Histogram 0.016
Fundamentals Value
Market Cap 39.75 Billion
Num Shares 219 Million
EPS 4.31
Price-to-Earnings (P/E) Ratio 42.16
Price-to-Sales 4.69
Price-to-Book 2.45
PEG Ratio 0.78
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 183.74
Resistance 3 (R3) 183.83 183.22 183.39
Resistance 2 (R2) 183.22 182.68 183.17 183.28
Resistance 1 (R1) 182.43 182.35 182.13 182.35 183.16
Pivot Point 181.82 181.82 181.67 181.78 181.82
Support 1 (S1) 181.04 181.29 180.73 180.95 180.14
Support 2 (S2) 180.43 180.96 180.38 180.02
Support 3 (S3) 179.64 180.43 179.91
Support 4 (S4) 179.56